SVF
Insufficient· Insufficient EvidenceNarrative Review

From Biological Waste to Therapeutic Resources: A Comprehensive Review of Stem Cell Sources, Characterization, and Biomedical Potentials.

Camia B., Monti M.

Narrative Review on Osteoarthritis, Cardiovascular Disease, Scar, Autoimmune Research, published in Stem Cell Rev Rep (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Stem Cell Rev Rep (2026)
Country
United States
Reported sample size
—
PMID
41091433
DOI
10.1007/s12015-025-10989-3

Abstract (original English)

The concept of utilizing biological waste as a resource dates back centuries, with early practices in traditional medicine repurposing discarded tissues for healing purposes. In recent decades, advances in stem cell biology have revitalized this concept by identifying multipotent stem cells within various waste materials, including urine, adipose tissue, follicular fluid, umbilical cord blood, fetal annexes, menstrual blood, and dental pulp byproducts. These sources offer a minimally invasive, ethically sound, and cost-effective alternative to conventional stem cell harvesting methods. Stem cells derived from waste materials exhibit robust proliferative abilities and multilineage differentiation potential, positioning them as valuable tools for regenerative medicine, tissue engineering, and personalized therapeutic applications. Clinical studies highlight their promise. For example, mesenchymal stem cells from adipose tissue and umbilical cord blood have shown safety and some effectiveness in early trials. These studies report improvements of up to 30-40% in recovery scores for osteoarthritis and ischemic heart disease, as well as a 20-35% decrease in inflammatory markers for autoimmune disorders. Cord blood stem cell transplants have shown 70-90% survival rates in children with blood cancers. This underscores the clinical potential of waste-derived stem cells. However, regulat

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

There is currently not enough data to draw conclusions about benefit or risk for this topic.

How we grade evidence
HumansRegenerative MedicineStem CellsAnimalsStem Cell TransplantationTissue Engineering
Systemic / IVOsteoarthritisCardiovascular DiseaseScarAutoimmune Research
View on PubMedDOI

Related research